Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Venous Thromboembolism 2Venous Thrombosis 1Vascular Diseases 1Urogenital Neoplasms 1Thromboembolism 1Prostatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1Intestinal Neoplasms 1Hemostatic Disorders 1Digestive System Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

apixaban 5Rivaroxaban 5Dalteparin 4Enoxaparin 3edoxaban 2abelacimab 2Tinzaparin 2MAA868 2Heparin, Low-Molecular-Weight 2Dabigatran 2isoquercitrin 1calcium heparin 1betrixaban 1bemiparin 1Warfarin 1Heparin 1Gemcitabine 1Fondaparinux 1AVE 5026 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Venous Thromboembolism × Tinzaparin × Clear all
NCT01130025 2025-02-24

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

LEO Pharma

Phase 3 Completed
900 enrolled
Classical hematology

Venous Thromboembolism

NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Digestive System Neoplasms, Intestinal Neoplasms, Leukemia, Lung Neoplasms, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Prostatic Neoplasms, Thromboembolism, Urogenital Neoplasms, Vascular Diseases, Colorectal Neoplasms, Hemostatic Disorders, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡